Celularity Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.3
- Today's High:
- $0.315
- Open Price:
- $0.3139
- 52W Low:
- $0.4
- 52W High:
- $7.43
- Prev. Close:
- $0.302
- Volume:
- 112824
Company Statistics
- Market Cap.:
- $125.76 million
- Book Value:
- 0.943
- Revenue TTM:
- $15.98 million
- Operating Margin TTM:
- -882.6%
- Gross Profit TTM:
- $-1690000
- Profit Margin:
- 81.64%
- Return on Assets TTM:
- -22.12%
- Return on Equity TTM:
- 10.62%
Company Profile
Celularity Inc had its IPO on 2019-08-08 under the ticker symbol CELU.
The company operates in the Healthcare sector and Biotechnology industry. Celularity Inc has a staff strength of 225 employees.
Stock update
Shares of Celularity Inc opened at $0.31 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.3 - $0.32, and closed at $0.31.
This is a +0.99% increase from the previous day's closing price.
A total volume of 112,824 shares were traded at the close of the day’s session.
In the last one week, shares of Celularity Inc have slipped by -15.28%.
Celularity Inc's Key Ratios
Celularity Inc has a market cap of $125.76 million, indicating a price to book ratio of 1.3244 and a price to sales ratio of 11.6308.
In the last 12-months Celularity Inc’s revenue was $15.98 million with a gross profit of $-1690000 and an EBITDA of $-131481000. The EBITDA ratio measures Celularity Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Celularity Inc’s operating margin was -882.6% while its return on assets stood at -22.12% with a return of equity of 10.62%.
In Q1, Celularity Inc’s quarterly earnings growth was a negative -92.5% while revenue growth was a negative 33.7%.
Celularity Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 4.3538
- PEG
Its diluted EPS in the last 12-months stands at $0.16 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Celularity Inc’s profitability.
Celularity Inc stock is trading at a EV to sales ratio of 12.9421 and a EV to EBITDA ratio of -62.0623. Its price to sales ratio in the trailing 12-months stood at 11.6308.
Celularity Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $362.42 million
- Total Liabilities
- $66.46 million
- Operating Cash Flow
- $-3209000.00
- Capital Expenditure
- $3.21 million
- Dividend Payout Ratio
- 0%
Celularity Inc ended 2024 with $362.42 million in total assets and $0 in total liabilities. Its intangible assets were valued at $362.42 million while shareholder equity stood at $155.63 million.
Celularity Inc ended 2024 with $9000.00 in deferred long-term liabilities, $66.46 million in other current liabilities, 17000.00 in common stock, $-709513000.00 in retained earnings and $90.06 million in goodwill. Its cash balance stood at $8.53 million and cash and short-term investments were $8.53 million. The company’s total short-term debt was $30,945,000 while long-term debt stood at $4.75 million.
Celularity Inc’s total current assets stands at $25.00 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $5.17 million compared to accounts payable of $8.76 million and inventory worth $5.48 million.
In 2024, Celularity Inc's operating cash flow was $-3209000.00 while its capital expenditure stood at $3.21 million.
Comparatively, Celularity Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.31
- 52-Week High
- $7.43
- 52-Week Low
- $0.4
- Analyst Target Price
- $9.88
Celularity Inc stock is currently trading at $0.31 per share. It touched a 52-week high of $7.43 and a 52-week low of $7.43. Analysts tracking the stock have a 12-month average target price of $9.88.
Its 50-day moving average was $0.39 and 200-day moving average was $0.74 The short ratio stood at 8.95 indicating a short percent outstanding of 0%.
Around 5977.9% of the company’s stock are held by insiders while 2221.5% are held by institutions.
Frequently Asked Questions About Celularity Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company’s lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin’s lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn’s disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products. The company was founded in 1998 and is based in Florham Park, New Jersey.